Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation ...Middle East

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid...

Hence then, the article about rigel announces availability of rezlidhia olutasidenib in the u s for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible idh1 mutation was published today ( Thursday 22/12/2022 - 04:24 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation )

Also on site :

• South Africa pushes for renewable energy investment
• SeaWorld in Texas Is Opening a First-of-Its-Kind Inverted Coaster This Spring
• Zelensky is ‘a man in a desperate position’ – Orban